Clinigen Group plc Result of AGM and Directorate Change (6807G)

TIDMCLIN

RNS Number : 6807G

Clinigen Group plc

26 November 2020

26 November 2020

Result of AGM and Resignation of Non-Executive Director

Clinigen Group plc (AIM: CLIN, 'Clinigen' or the 'Group'), the global pharmaceutical and services company, held its Annual General Meeting ('AGM') today at which all resolutions were passed. Resolutions 1-15 were passed as Ordinary Resolutions and Resolutions 14 and 15 were passed as Special Resolutions.

As previously announced in September 2020, John Hartup the Senior Independent Non-Executive Director, decided not to stand for re-election at the AGM and therefore, he has resigned as a Director of the Company with effect from today, 26 November. Consequently, Anne Hyland has been appointed as the Senior Independent Director and Alan Boyd has been appointed to engage with the workforce on behalf of the board as the designated Non-Executive Director. Both of these appointments are effective from 26 November 2020. The Nomination Committee has also started the search process for a new independent Non-Executive Director.

The voting results at the AGM are given in the table below.

 
                                                               For               Against     Discretionary 
                                                                                              / Withheld 
 Resolution                                         Number         %      Number       %            Number 
                                              ------------  --------  ----------  ------  ---------------- 
  1. To receive the audited financial 
   statements and the Auditors' and 
   Directors' Reports for the year 
   ended 30 June 2020.                          94,363,546   100.00%         285   0.00%            89,188 
                                              ------------  --------  ----------  ------  ---------------- 
  2. To approve the Directors' Remuneration 
   Report (other than the part containing 
   the Directors' remuneration policy) 
   for the year ended 30 June 2020.             89,044,191    94.28%   5,404,286   5.72%             4,542 
                                              ------------  --------  ----------  ------  ---------------- 
  3. To declare a final dividend 
   of 5.46p per share for the year 
   ended 30 June 2020.                          94,451,582   100.00%         285   0.00%             1,152 
                                              ------------  --------  ----------  ------  ---------------- 
  4. To re-elect Peter Allen as 
   a Director.                                  82,526,572    87.38%  11,918,235  12.62%             8,212 
                                              ------------  --------  ----------  ------  ---------------- 
  5. To re-elect Ian Nicholson as 
   a Director.                                  92,566,213    98.02%   1,866,630   1.98%            20,176 
                                              ------------  --------  ----------  ------  ---------------- 
  6. To re - elect Anne Hyland as 
   a Director.                                  93,911,041    99.45%     521,802   0.55%            20,176 
                                              ------------  --------  ----------  ------  ---------------- 
  7. To re - elect Alan Boyd as 
   a Director.                                  79,091,727    83.93%  15,138,298  16.07%           222,994 
                                              ------------  --------  ----------  ------  ---------------- 
  8. To re - elect Shaun Chilton 
   as a Director.                               93,543,054    99.04%     906,789   0.96%             3,176 
                                              ------------  --------  ----------  ------  ---------------- 
  9. To re-elect Nick Keher as a 
   Director.                                    93,258,324    98.74%   1,191,674   1.26%             3,021 
                                              ------------  --------  ----------  ------  ---------------- 
  10. To reappoint PricewaterhouseCoopers 
   LLP 
   as auditors.                                 91,007,732    96.36%   3,438,680   3.64%             6,607 
  11. To authorise the Directors 
   to determine the auditors' remuneration.     91,800,589    97.20%   2,640,554   2.80%            11,876 
                                              ------------  --------  ----------  ------  ---------------- 
  12. To grant the Company authority 
   to make political donations.                 80,071,917    91.21%   7,715,738   8.79%         6,665,364 
                                              ------------  --------  ----------  ------  ---------------- 
  13. To authorise the Directors 
   to allot shares pursuant to section 
   551 of the Companies Act 2006.               93,845,132    99.36%     601,552   0.64%             6,335 
  14. To empower the Directors to 
   disapply pre-emption rights.                 89,624,066    94.90%   4,820,119   5.10%             8,834 
                                              ------------  --------  ----------  ------  ---------------- 
  15. To empower the Directors to 
   disapply pre-emption rights in 
   relation to shares issued in connection 
   with an acquisition or specified 
   capital investment.                          88,456,906    93.66%   5,986,979   6.34%             9,134 
                                              ------------  --------  ----------  ------  ---------------- 
 

Note: As at 26 November 2020, Clinigen has 133,028,647 ordinary shares of 0.1 pence each in issue and the total number of voting rights is 133,028,647 .

- Ends -

For further information, please contact:

 
 Clinigen Group plc                             Tel: [phone] 
                                                 010 
 Shaun Chilton, Group Chief Executive Officer 
  Nick Keher, Group Chief Financial Officer 
 
 J.P.Morgan Cazenove - Nominated Adviser &      Tel: [phone] 
  Joint Broker                                   4000 
 James Mitford / Hemant Kapoor 
 
 RBC Capital Markets - Joint Broker             Tel: [phone] 
                                                 4000 
 Marcus Jackson / Elliot Thomas 
 
 Instinctif Partners                            Tel: [phone] 
                                                 2020 
 Melanie Toyne Sewell / Phillip Marriage        Email: [e-mail] 
 

About Clinigen Group

Clinigen Group plc (AIM: CLIN) is a global pharmaceutical and services company with a unique combination of businesses focused on providing ethical access to medicines. Its mission is to deliver the right medicine to the right patient at the right time through three areas of global medicine supply; clinical trial, unlicensed and licensed medicines. The Group has sites in North America, Europe, Africa and the Asia Pacific region.

Clinigen now has over 1,150 employees across five continents in 14 countries, with supply and distribution hubs and operational centres of excellence in key long term growth regions. The Group works with 21 of the top 25 pharmaceutical companies; interacting with over 18,000 registered users across 115 countries, shipping approximately 6.5 million units in the year.

For more information on Clinigen, please visit www.clinigengroup.com .

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

RAGFLFFRLDLRFII

(END) Dow Jones Newswires

November 26, 2020 11:28 ET (16:28 GMT)